NYSE:EBS Emergent BioSolutions (EBS) Stock Price, News & Analysis → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Free EBS Stock Alerts $2.04 +0.18 (+9.68%) (As of 04/19/2024 ET) Add Compare Share Share Today's Range$1.86▼$2.0650-Day Range$1.53▼$3.4152-Week Range$1.42▼$10.88Volume935,665 shsAverage Volume2.71 million shsMarket Capitalization$106.88 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Emergent BioSolutions alerts: Email Address Emergent BioSolutions MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside145.1% Upside$5.00 Price TargetShort InterestBearish11.38% of Float Sold ShortDividend StrengthN/ASustainability-1.40Upright™ Environmental ScoreNews Sentiment0.33Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($13.98) to ($0.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.78 out of 5 starsMedical Sector215th out of 911 stocksPharmaceutical Preparations Industry82nd out of 409 stocks 3.0 Analyst's Opinion Consensus RatingEmergent BioSolutions has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.Amount of Analyst CoverageEmergent BioSolutions has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.38% of the float of Emergent BioSolutions has been sold short.Short Interest Ratio / Days to CoverEmergent BioSolutions has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Emergent BioSolutions has recently increased by 16.09%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEmergent BioSolutions does not currently pay a dividend.Dividend GrowthEmergent BioSolutions does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEmergent BioSolutions has received a 73.60% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Influenza vaccines", "Cholera vaccines", and "Antibiotics" products. See details.Environmental SustainabilityThe Environmental Impact score for Emergent BioSolutions is -1.40. Previous Next 1.9 News and Social Media Coverage News SentimentEmergent BioSolutions has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Emergent BioSolutions this week, compared to 2 articles on an average week.Search InterestOnly 8 people have searched for EBS on MarketBeat in the last 30 days. This is a decrease of -82% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Emergent BioSolutions to their MarketBeat watchlist in the last 30 days. This is a decrease of -58% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Emergent BioSolutions insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.90% of the stock of Emergent BioSolutions is held by insiders.Percentage Held by Institutions78.40% of the stock of Emergent BioSolutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Emergent BioSolutions are expected to grow in the coming year, from ($13.98) to ($0.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Emergent BioSolutions is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Emergent BioSolutions is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEmergent BioSolutions has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Emergent BioSolutions Stock (NYSE:EBS)Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.Read More EBS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EBS Stock News HeadlinesApril 17, 2024 | finance.yahoo.comInstitutional owners may take dramatic actions as Emergent BioSolutions Inc.'s (NYSE:EBS) recent 16% drop adds to one-year lossesApril 13, 2024 | americanbankingnews.comEmergent BioSolutions (NYSE:EBS) Stock Rating Reaffirmed by BenchmarkApril 20, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 1, 2024 | finance.yahoo.comAquestive Therapeutics Strengthens Board of Directors with Experienced Biotech ExecutiveMarch 28, 2024 | globenewswire.comEmergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid CrisisMarch 27, 2024 | bizjournals.comWhy this Maryland biotech furloughed 130 workers in MichiganMarch 25, 2024 | globenewswire.comEmergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing FacilityMarch 12, 2024 | marketwatch.comEmergent BioSolutions Shares Drop on S&P DowngradeApril 20, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 7, 2024 | realmoney.thestreet.comBenchmark gets more bullish on Emergent BioSolutions, upgrades sharesMarch 7, 2024 | realmoney.thestreet.comEmergent BioSolutions upgraded to Buy at Benchmark after 'upbeat' Q4 reportMarch 7, 2024 | finance.yahoo.comEmergent BioSolutions Inc (EBS) Reports Mixed Fourth Quarter and Full Year 2023 Financial ResultsMarch 7, 2024 | finance.yahoo.comEmergent BioSolutions Inc. (NYSE:EBS) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finance.yahoo.comQ4 2023 Emergent BioSolutions Inc Earnings CallMarch 7, 2024 | fool.comEmergent BioSolutions (EBS) Q4 2023 Earnings Call TranscriptMarch 6, 2024 | investorplace.comEBS Stock Earnings: Emergent BioSolutions Misses EPS, Misses Revenue for Q4 2023March 6, 2024 | benzinga.comEmergent BioSolutions: Q4 Earnings InsightsMarch 6, 2024 | globenewswire.comEmergent BioSolutions Reports Fourth Quarter 2023 Financial ResultsMarch 6, 2024 | globenewswire.comEmergent BioSolutions Reports Fourth Quarter 2023 Financial ResultsMarch 6, 2024 | msn.comEmergent Biosolutions Q4 2023 Earnings PreviewMarch 4, 2024 | benzinga.comEmergent BioSolutions's Earnings: A PreviewFebruary 29, 2024 | globenewswire.comEmergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024February 27, 2024 | seekingalpha.comNew CEO Appointment A Clear Positive For Emergent BioSolutionsFebruary 21, 2024 | bizjournals.comBiotech with Baltimore facility taps new CEOFebruary 21, 2024 | investorplace.comWhy Is Emergent BioSolutions (EBS) Stock Up 70% Today?February 21, 2024 | investorplace.comWhy Is Emergent BioSolutions (EBS) Stock Up 70% Today?February 21, 2024 | msn.comTeladoc Health, Avinger among healthcare moversSee More Headlines Receive EBS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today4/20/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNYSE:EBS CUSIP29089Q10 CIK1367644 Webwww.emergentbiosolutions.com Phone(240) 631-3200Fax301-795-1899Employees1,600Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+145.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($14.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-760,500,000.00 Net Margins-72.11% Pretax Margin-69.68% Return on Equity-37.35% Return on Assets-14.81% Debt Debt-to-Equity Ratio0.69 Current Ratio1.04 Quick Ratio0.54 Sales & Book Value Annual Sales$1.02 billion Price / Sales0.10 Cash Flow$0.94 per share Price / Cash Flow2.16 Book Value$12.51 per share Price / Book0.16Miscellaneous Outstanding Shares52,391,000Free Float51,396,000Market Cap$106.88 million OptionableOptionable Beta1.20 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Richard S. Lindahl M.B.A. (Age 60)Executive VP, CFO & Treasurer Comp: $799.38kMs. Jennifer L. FoxExecutive VP of External Affairs, General Counsel & Corporate SecretaryMr. Joseph C. Papa Jr. (Age 68)CEO & President Mr. Robert G. BurrowsVice President of Investor RelationsMs. Coleen GlessnerExecutive Vice President of Global Quality and Ethics & ComplianceMichelle PepinSenior VP & Chief Human Resource OfficerMs. Stephanie DuatschekSenior VP, Chief Strategy & Transformation OfficerDr. Kelly Lyn WarfieldSenior VP of Science & DevelopmentMr. Paul A. WilliamsSenior Vice President of Products BusinessWilliam HartzelSenior Vice President of Manufacturing & BioservicesMore ExecutivesKey CompetitorsBolt BiotherapeuticsNASDAQ:BOLTRegulus TherapeuticsNASDAQ:RGLSFortress BiotechNASDAQ:FBIORigel PharmaceuticalsNASDAQ:RIGLVanda PharmaceuticalsNASDAQ:VNDAView All CompetitorsInsiders & InstitutionsSeaCrest Wealth Management LLCBought 96,000 shares on 4/18/2024Ownership: 0.183%Los Angeles Capital Management LLCBought 32,460 shares on 4/5/2024Ownership: 0.372%Vanguard Group Inc.Bought 328,272 shares on 3/11/2024Ownership: 5.734%Goldman Sachs Group Inc.Bought 93,301 shares on 3/1/2024Ownership: 1.449%Virtu Financial LLCBought 12,623 shares on 2/26/2024Ownership: 0.057%View All Insider TransactionsView All Institutional Transactions EBS Stock Analysis - Frequently Asked Questions Should I buy or sell Emergent BioSolutions stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last year. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" EBS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EBS, but not buy additional shares or sell existing shares. View EBS analyst ratings or view top-rated stocks. What is Emergent BioSolutions' stock price target for 2024? 2 brokerages have issued twelve-month price objectives for Emergent BioSolutions' stock. Their EBS share price targets range from $5.00 to $5.00. On average, they expect the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 145.1% from the stock's current price. View analysts price targets for EBS or view top-rated stocks among Wall Street analysts. How have EBS shares performed in 2024? Emergent BioSolutions' stock was trading at $2.40 at the beginning of the year. Since then, EBS shares have decreased by 15.0% and is now trading at $2.04. View the best growth stocks for 2024 here. Are investors shorting Emergent BioSolutions? Emergent BioSolutions saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 5,700,000 shares, an increase of 16.1% from the March 15th total of 4,910,000 shares. Based on an average daily volume of 2,980,000 shares, the short-interest ratio is presently 1.9 days. Currently, 11.4% of the shares of the company are sold short. View Emergent BioSolutions' Short Interest. When is Emergent BioSolutions' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our EBS earnings forecast. How were Emergent BioSolutions' earnings last quarter? Emergent BioSolutions Inc. (NYSE:EBS) released its earnings results on Wednesday, March, 6th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by $0.44. The biopharmaceutical company earned $276.60 million during the quarter, compared to analyst estimates of $247.63 million. Emergent BioSolutions had a negative trailing twelve-month return on equity of 37.35% and a negative net margin of 72.11%. During the same period in the prior year, the company posted ($0.31) EPS. What ETF holds Emergent BioSolutions' stock? Amplify Treatments, Testing and Advancements ETF holds 14,243 shares of EBS stock, representing 0.70% of its portfolio. What guidance has Emergent BioSolutions issued on next quarter's earnings? Emergent BioSolutions issued an update on its first quarter 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $200.0 million-$250.0 million, compared to the consensus revenue estimate of $185.4 million. What is Bob Kramer's approval rating as Emergent BioSolutions' CEO? 38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among the company's employees. What other stocks do shareholders of Emergent BioSolutions own? Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), Salesforce (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Block (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV). Who are Emergent BioSolutions' major shareholders? Emergent BioSolutions' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.37%) and SeaCrest Wealth Management LLC (0.18%). Insiders that own company stock include Kathryn C Zoon, Richard S Lindahl and Ronald Richard. View institutional ownership trends. How do I buy shares of Emergent BioSolutions? Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:EBS) was last updated on 4/20/2024 by MarketBeat.com Staff From Our PartnersBiden’s $374B Giveaway Into This SectorDTISHOCKING Crypto Leak…Crypto 101 MediaThe #1 Crypto for 2024InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent alert: open this for a huge profit potentialTimothy SykesTiny Biotech Stock Wins $75 Billion PatentBehind the MarketsHow Biden has already won 2024Porter & CompanyTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emergent BioSolutions Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.